The global pharmaceutical inspection machines market size is calculated at US$ 0.96 billion in 2024, grew to US$ 1.04 billion in 2025, and is projected to reach around US$ 1.96 billion by 2034. The market is expanding at a CAGR of 7.56% between 2025 and 2034.
Rising Demand for Serialization and Anti-Counterfeit Measures: Inspection devices with serialization and track and trace capabilities are in greater demand as worries about fake medications grow. These systems protect the public's health by guaranteeing product authenticity and adherence to international regulatory standards.
Focuses on AI-enabled vision, automation, and compact modular design to improve speed and accuracy in defect detection. Companies are also advancing machine learning algorithms for real-time defect classification and predictive quality control. This helps manufacturers cut errors, enhance throughput, and lower operational costs.
Key players include: Korber AG, Syntegon Technology GmbH, Antares Vision S.p.A., and ACG inspection.
Makes sure that equipment complies with FDA, EMA, and cGMP regulations and is validated for dependability and safety in pharmaceutical manufacturing. For delicate drug classes like injectables and biologics, compliance also helps with risk management and traceability. This phase increases machine adoption in international markets and fosters regulator trust.
Key Players include: Cognex Corporation, METTLER TOLEDO, Brevetti CEA S.p.A., Nikka Densok Limited.
Although patients are indirect beneficiaries, inspection machines ensure that drugs reaching them are free from defects, contamination, or labeling errors. Service providers focus on training pharma staff, offering preventive maintenance, and deploying cloud-enabled monitoring for continuous machine optimization. Ultimately, these systems safeguard patient safety and maintain confidence in drug quality.
Key Players Include: ACG Inspection, Brevetti CEA S.p.A., Syntegon Technology GmbH, Körber AG
In June 2025, Antares Vision Group launched AI GO, an advanced artificial intelligence-driven visual inspection platform, developed in collaboration with Orobix, an AI service company and part of Antares Vision Group. This platform aims to elevate inspection standards by enabling systems capable of understanding, self-adapting, and continuously improving. Gianluca Mazzantini, CEO of Antares Vision Group, stated that AI integration enhances industrial competitiveness by improving product quality, reducing false rejects, and increasing production efficiency.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
